SEC Filing :: ADMA Biologics, Inc.

View:

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 R&R Acquisition VI, Inc. - -------------------------------------------------------------------------------- (Name of Issuer) Common Stock, par value $.0001 per share - -------------------------------------------------------------------------------- (Title of Class of Securities) None - -------------------------------------------------------------------------------- (CUSIP Number) Arnold P. Kling 712 Fifth Avenue, 11th Floor New York, NY 10019 (212) 755-8777 - -------------------------------------------------------------------------------- (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) September 8, 2006 - -------------------------------------------------------------------------------- (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of ss.ss.240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. [ ] The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. None - -------------------------------------------------------------------------------- 1. Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only). Arnold P. Kling - -------------------------------------------------------------------------------- 2. Check the Appropriate Box if a Member of a Group (See Instructions) (a) (b) - -------------------------------------------------------------------------------- 3. SEC Use Only - -------------------------------------------------------------------------------- 4. Source of Funds (See Instructions) (See item 3) PF - -------------------------------------------------------------------------------- 5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) - -------------------------------------------------------------------------------- 6. Citizenship or Place of Organization U.S.A. - -------------------------------------------------------------------------------- 7. Sole Voting Power Number of 400,000 Shares --------------------------------------------------------------- Beneficially 8. Shared Voting Power Owned by --------------------------------------------------------------- Each 9. Sole Dispositive Power Reporting 400,000 Person With --------------------------------------------------------------- 10. Shared Dispositive Power - -------------------------------------------------------------------------------- 11. Aggregate Amount Beneficially Owned by Each Reporting Person 400,000 - -------------------------------------------------------------------------------- 12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) - -------------------------------------------------------------------------------- 13. Percent of Class Represented by Amount in Row (11) 16% - -------------------------------------------------------------------------------- 14. Type of Reporting Person (See Instructions) IN

Item 1. Security and Issuer. This Schedule 13D relates to the common stock, par value $.0001 per share (the "Common Stock") of R&R Acquisition VI, Inc., whose principal executive offices are located at c/o Kirk M. Warshaw, 47 School Avenue, Chatham, New Jersey 07928 (the "Issuer"). Item 2. Identity and Background. (a) The name of the reporting person is Arnold P. Kling (the "Reporting Person"). (b) The business address of the Reporting Person is 712 Fifth Avenue, 11th Floor, New York, New York 10019. (c) The Reporting Person's present principal occupation or employment and the name, principal business and address of any corporation or other organization in which such employment is conducted is Managing Director of GH Venture Partners, LLC, located at 712 Fifth Avenue, 11th Floor, New York, New York 10019. (d) During the last five years the Reporting Person has not been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors). (e) During the last five years the Reporting Person was not a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result was not or is not subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws. (f) The Reporting Person is a citizen of the U.S.A. Item 3. Source and Amount of Funds or Other Consideration. The Reporting Person acquired directly from the Issuer 400,000 shares Common Stock at an aggregate price of $40, or $.0001 per share. The source of funding for this purchase was through personal funds. Item 4. Purpose of Transaction. None. Item 5. Interest in Securities of the Issuer. (a) The Reporting Person beneficially owns an aggregate of 400,000 shares of Common Stock, representing 16% of the outstanding shares of Common Stock (based, as to the number of outstanding shares, upon the Issuer's Form 10-SB filed July 10, 2006.) (b) The Reporting Person has the sole right to vote and dispose, or direct the disposition, of the 400,000 shares of Common Stock owned by the Reporting Person. (c) The 400,000 shares of Common Stock reported herein were acquired by the Reporting Person effective June 8, 2006. (d) Other than the Reporting Person, no other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the 400,000 shares of Common Stock owned by the Reporting Person. (e) Not applicable. Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer. None. Item 7. Material to Be Filed as Exhibits. None.

Signature. After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. September 8, 2006 ARNOLD P. KLING /s/ Arnold P. Kling -----------------------------------